— Research note —
Cerebrolysin
Porcine brain-derived peptide preparation investigated for neurotrophic activity in stroke and neurodegenerative research models.
Cerebrolysin is a peptide preparation derived from enzymatically processed porcine brain tissue, manufactured by EVER Neuro Pharma in Austria. The product consists of a complex mixture of low-molecular-weight peptides (below approximately 10 kDa) and free amino acids generated through controlled proteolytic digestion of lipid-free brain protein. The exact composition has been characterized in proteomic studies as containing fragments derived from neurotrophic proteins, including portions of BDNF, CNTF, and GDNF, alongside free amino acids and other small peptide species.
Unlike single defined peptides, cerebrolysin is a regulated multi-component biological preparation. The product has been approved in multiple jurisdictions including Russia, China, and parts of Europe for use in clinical research and pharmaceutical application in ischemic stroke, traumatic brain injury, and neurodegenerative disorders. The preparation has been the subject of extensive clinical investigation, with meta-analyses and Cochrane reviews examining outcomes in stroke and dementia research populations.
In preclinical models, cerebrolysin has been observed to support neuronal survival in cultures exposed to oxidative stress, glutamate excitotoxicity, and amyloid-beta toxicity. Mechanistic studies have reported effects mimicking those of endogenous neurotrophic factors, including activation of TrkB signaling, reduction of apoptotic markers, and modulation of amyloid precursor protein processing. The complex composition of the preparation complicates mechanistic interpretation, and ongoing research continues to characterize the active peptide components responsible for the observed effects.
Cerebrolysin is supplied here as ampoules for laboratory research use only and is not intended for human consumption outside of approved clinical research contexts in regulated jurisdictions. Its primary research applications include neuroprotection studies, BDNF-related signaling research, and characterization of complex multi-component peptide preparations.
Mechanism
The proposed mechanism of action of cerebrolysin involves multi-targeted neurotrophic and neuroprotective effects mediated by the low-molecular-weight peptide fraction. The preparation has been reported to engage TrkB and TrkA receptor signaling in a manner reminiscent of endogenous BDNF and NGF, activating downstream CREB and ERK pathways that support neuronal survival and plasticity.
Additional mechanisms documented in preclinical studies include modulation of amyloid precursor protein processing, reduction of caspase-3 activation in models of neuronal injury, attenuation of glutamate excitotoxicity, and reduction of oxidative stress markers. In stroke models, the preparation has been associated with reductions in infarct volume and preservation of neurological function. In Alzheimer's disease preclinical models, effects on amyloid pathology and synaptic markers have been reported. The complex composition of the preparation precludes attribution of specific effects to single peptide species, and active component identification remains an area of continued investigation.
Research history
Cerebrolysin was developed in the 1970s by Austrian researchers at EBEWE Arzneimittel (subsequently EVER Neuro Pharma) using controlled enzymatic digestion of porcine brain tissue. The preparation entered European and Russian clinical practice in the 1970s and 1980s for various neurological indications.
Clinical research has examined the preparation in multiple contexts. Acute ischemic stroke trials, including the CASTA and CARS studies in Asian and European populations, have reported variable effects on neurological recovery endpoints. Trials in vascular dementia and Alzheimer's disease have generated additional data, with some meta-analyses suggesting modest improvements in cognitive endpoints. Traumatic brain injury research has included pediatric and adult cohorts.
Preclinical mechanistic research has continued to characterize the neurotrophic effects of the preparation, with publications from European, Russian, Chinese, and other research groups extending into 2025. Proteomic and peptidomic studies have identified individual peptide components, although the relative contribution of specific species to observed pharmacological effects has not been fully resolved. The preparation has become a frequently studied reference for multi-component peptide neuroprotection research and a continuing subject of clinical investigation in stroke and dementia.
References
- Heiss WD, et al. 2012. Cerebrolysin in patients with acute ischemic stroke in Asia: results of a double-blind, placebo-controlled randomized trial. Stroke. PMID: 22033998
- Muresanu DF, et al. 2016. Cerebrolysin and Recovery After Stroke (CARS): A Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial. Stroke. PMID: 26486868
- Alvarez XA, et al. 2011. Cerebrolysin in Alzheimer's disease: a comprehensive review. Drugs Aging.
- Plosker GL, Gauthier S. 2009. Cerebrolysin: a review of its use in dementia. Drugs Aging. PMID: 19891492
- Chen N, et al. 2013. Cerebrolysin for vascular dementia. Cochrane Database Syst Rev. PMID: 23440844
- Zhang L, et al. 2010. Cerebrolysin enhances neurogenesis in the ischemic brain and improves functional outcome after stroke. J Neurosci Res. PMID: 20127807
Do you have any questions about Cerebrolysin?
Pick a path. The research assistant has the full literature context loaded.
Information presented in third-person scientific context. Research use only. Not medical advice; not for human consumption.